BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27888377)

  • 1. Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.
    Li H; Cao J; Zhang X; Song X; Wang W; Jia S; Li Z; Jia H; Cao X; Zhou W; Lian J; Han S; Yang W; Xi Y; Lian S; Jing H
    Clin Exp Metastasis; 2017 Jan; 34(1):63-71. PubMed ID: 27888377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
    Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
    Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases.
    Yang H; Cai L; Zhang Y; Tan H; Deng Q; Zhao M; Xu X
    J Mol Diagn; 2014 Sep; 16(5):558-563. PubMed ID: 24994671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
    PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
    Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impacts of EGFR 19 exon mutations on brain metastases in treatment-naïve patients with lung adenocarcinoma].
    Wang WL; Li HW; Cao JZ; Zhang XQ; Song X; Jia SF; Jia HX
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):744-748. PubMed ID: 29061017
    [No Abstract]   [Full Text] [Related]  

  • 9. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis.
    Rau KM; Chen HK; Shiu LY; Chao TL; Lo YP; Wang CC; Lin MC; Huang CC
    Int J Mol Sci; 2016 Apr; 17(4):524. PubMed ID: 27070580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
    Zhou J; Ben S
    Thorac Cancer; 2018 Feb; 9(2):228-233. PubMed ID: 29222872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.
    Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J
    Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
    Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
    Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
    Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
    Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic model for brain metastases from lung adenocarcinoma identified with epidermal growth factor receptor mutation status.
    Li H; Wang W; Jia H; Lian J; Cao J; Zhang X; Song X; Jia S; Li Z; Cao X; Zhou W; Han S; Yang W; Xi Y; Lian S
    Thorac Cancer; 2017 Sep; 8(5):436-442. PubMed ID: 28597503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.